BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400
info@bellbrooklabs.com
Quick Answer: Even well-developed assays can lead to delays in high-throughput screening (HTS) campaigns due to: Scaling challenges from development to screening formats Data quality issues under real screening conditions False positives that slow hit validation Workflow complexity limiting throughput Lack of clear criteria for “screen-ready” assays The most successful screening programs anticipate these challenges […]
Quick Answer: Contract research organizations (CROs) can reduce high-throughput screening (HTS) costs without sacrificing data quality by focusing on four key levers: Improve reagent efficiency to reduce cost per well Select assay formats that minimize interference and rework Reduce false positives to avoid costly downstream validation Simplify workflows to increase throughput and consistency The most […]
Quick Answer To optimize kinase assays for Z′, sensitivity, and cost, systematically tune enzyme and substrate concentrations, use ATP near Km, select an appropriate time window, and validate DMSO tolerance and controls early. Small, structured experiments—especially enzyme titration and time course—drive the biggest gains. Efficient assay formats and minimized reagent usage can reduce costs without […]
Quick Answer Kinase activity in high-throughput screening (HTS) is typically measured by detecting either ATP consumption, ADP production, or substrate phosphorylation. Common assay formats include ADP detection assays, phosphorylation-specific antibody assays, luminescent ATP/ADP assays, radiometric assays, mobility-shift assays, and fluorescence polarization or TR-FRET–based approaches. The best method depends on factors such as throughput requirements, susceptibility […]
Quick Answer: Kinase screens produce false positives when compounds interfere with assay detection, aggregate nonspecifically, undergo redox cycling, compete artificially with ATP or substrate, or disrupt assay components like luciferase. Many apparent “hits” inhibit the assay system rather than the kinase itself. Reducing false positives requires prevention-first assay design, followed by structured triage using filters, […]
TL;DR Fluorescent and luminescent readouts rely on fundamentally different detection chemistries, which influence sensitivity, interference risk, workflow complexity, and cost. Luminescence is not inherently more sensitive. Well-designed direct detection fluorescent assays can be equally or even ~10× more sensitive in certain kinase contexts. Compound interference profiles differ: fluorescence is vulnerable to optical artifacts; luminescence is […]
Quick Answer For enzyme inhibition studies in high-throughput screening (HTS), direct detection activity assays are the preferred default primary screening format. They offer higher practical throughput, fewer interference layers, and clearer mechanistic readouts than coupled or luminescent systems. Coupled and luminescent assays remain valuable but are often best positioned as orthogonal or secondary confirmation tools. […]
Quick Answer Common assay interference mechanisms in biochemical HTS include fluorescence artifacts (auto-fluorescence and quenching), compound aggregation, redox cycling, reactive chemistry, metal chelation, detergent sensitivity, luciferase modulation, and PAINS-related liabilities. These effects can create false positives or false negatives that distort screening results. The most reliable way to avoid assay interference is to combine thoughtful […]
Quick Answer: Why Is My Z′ Factor Low? A low Z′ factor usually means your assay lacks sufficient signal window, has excessive variability, or both. In biochemical assays, this is most often caused by poorly defined controls, enzyme or reagent instability, timing mismatches, plate effects, or avoidable technical variance introduced during liquid handling or detection. […]